Skip to content

Advances in Motion

ASCO 2024 Meeting Highlights

Article

In This Article

  • The American Society of Clinical Oncology (ASCO) Annual Meeting brings together thousands of international oncology professionals to share updates on clinical advances across every area of cancer research
  • In these videos, Mass General Cancer Center Physician-Scientists Priscilla Brastianos, MD, Lecia Sequist, MD, MPH, and Jessica Lin, MD, share highlights from the ASCO 2024 conference
  • They discuss encouraging results from a clinical trial for patients with high grade meningiomas, a new treatment for stage III unresectable EGFR lung cancer, and a palliative care trial

At this year's American Society of Clinical Oncology (ASCO) Annual Meeting, several Mass General Cancer Center leaders presented exciting updates in research and clinical advancements. In these videos, physician-scientists Priscilla Brastianos, MD, Lecia Sequist, MD, MPH, and Jessica Lin, MD, share highlights from their presentations at ASCO 2024.

Dr. Brastianos, director of the Central Nervous System Metastasis Center, presented encouraging results from a clinical trial for patients with high grade meningiomas. Dr. Sequist, program director of the Cancer Early Detection and Diagnostics Clinic, shared a new treatment for stage III unresectable EGFR lung cancer. Finally, Dr. Lin, attending physician in the Center for Thoracic Cancers and the Termeer Center for Targeted Therapies, discussed a palliative care trial co-led by Mass General Cancer Center Principal Investigators Joseph Greer, PhD, and Jennifer Temel, MD.

Dr. Brastianos: Alliance Clinical Trial

Dr. Sequist: Unresectable EGFR Lung Cancer

Dr. Lin: Palliative Care & Telehealth

Read more about Mass General Cancer Center at ASCO 2024

Learn about cancer care at Mass General

Related topics

Related

Keith Flaherty, MD, director of clinical research at Mass General Cancer Center and program co-chair of this year's AACR Annual Meeting, shares key highlights and favorite talks from the conference.

Oncology, Research and Innovation

Article

Related

Lecia V. Sequist, MD, MPH, Florian J. Fintelmann, MD, and colleagues have created and validated Sybil, a convolutional neural network that requires only one low-dose CT scan to predict future lung cancer, regardless of whether visible lung nodules are present and possibly independent of the patient's smoking history.

Artificial Intelligence, Lung Cancer, Oncology, Pulmonary and Critical Care

Journal